AYTU Insider Trading Activity and SEC Form 4 Filings
AYTU insider trading summary
No open-market insider purchases or sales of Aytu Biopharma, Inc (AYTU) have been reported on SEC Form 4 in the past 12 months.
Latest AYTU insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 9, 2025 | Joshua R. Disbrow | Chief Executive Officer | Buy | $100K (66,666 @ $1.50) |
| Jun 9, 2025 | Jarrett Disbrow | Chief Business Officer | Buy | $25K (16,666 @ $1.50) |
| Feb 28, 2025 | Joshua R. Disbrow | Chief Executive Officer | Buy | $20K (15,000 @ $1.30) |
| Jun 16, 2023 | Greg Pyszczymuka | Chief Commerical Officer | Buy | $22K (12,000 @ $1.87) |
| Jun 14, 2023 | Joshua R. Disbrow | Chief Executive Officer | Buy | $26K (14,000 @ $1.86) |
| Dec 19, 2022 | Greg Pyszczymuka | Chief Commercial Officer | Buy | $24K (100,000 @ $0.24) |
| Dec 19, 2022 | Joshua R. Disbrow | Chief Executive Officer | Buy | $25K (112,371 @ $0.22) |
| Dec 11, 2020 | Steven Boyd | Director | Buy | $8.0M (1,333,334 @ $6.00) |
| Dec 11, 2020 | Steven Boyd | Director | Buy | $0 (0 @ $0.00) |
| Dec 11, 2020 | Armistice Capital, LLC | Director | Buy | $0 (0 @ $0.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.